Topics:  Accessing Innovation: how to build efficient partnerships?  Innovation Map 2014  New funding sources: roadmap to a successful financing plan  Understanding Intellectual Property  Innovation is also Empowerment  Digital Health Forum: bringing disruptive technologies to medicines & healthcare  Big Data Revolution: accelerating value and Innovation  Biotech meets Medtech  Best of Innovation: Presenting companies Speakers:  Jean Deregnaucourt, Executive Vice President Business Development, Institut Pasteur  Michel Hubert, Business Development Advisor, Inventiva  Patrick Korman, VP Europe Business Development, Myriad Genetics  Pascal Touchon, Head of Business Development & Scientific Cooperation, Servier  Rafi Mardachti, CEO & President, Universal Medica Group  Thierry Laugel, Managing Partner, KLS Partners  Sascha Alivovic, VP Corporate Finance & Corporate Development, Morphosys AG  David Donabedian, VP, Head of Ventures & Early stage Collaborations, AbbVie  Fei Tian, Investment Analyst, Vesalius Biocapital  Cécile Theard-Jallu, Partner, Operations Division, De Gaulle-Fleurance & Associés  Eric Enderlin, Patent and Trademark attorney, Novagraaf  Francine Le Pechon-Joubert, Partner, De Gaulle-Fleurance & Associés  Matthias Borst, VP/General Manager DC, BD Medical WE & EMA, Becton Dickinson  Alexander Natz, Secretary General, EUCOPE  Jack Whelan, Research Advocate, ePatient  Uwe Diegel, President, iHealthLabs Europe  Isabelle Hilali, Vice President, Strategy & Marketing, Orange Healthcare  Andreas Lymberis, Research Program Officer, European Commission  Roberto Ascione, President, Razorfish Healthcare  Jan-Christoph Loh, CEO, Medexo  Cyril Grospiron, Business Development Manager, Umanlife  Patrice P. Denefle, Senior Partner & Co-founder, MedBioMix Partners  Bernard Courtieu, CEO, Integragen SA  Mike Furness, Senior Account Manager, DNA Nexus  Duane Schulthess, Managing Director, Vital Transformation  Andy Anderson, International Product Manager, Roche Diagnostics International Ltd  Francois Lacombe, Chief Scientific Officer, Mauna Kea Technologies  Nathalie Moll, Secretary General, EuropaBio  Nick Dunscombe, Head, Alliance & Integration Management, AstraZeneca  Frank Grams, VP, Head Alliance Management & Transactions, Sanofi R&D  Stephan Lensky,VP Strategic Transactions & Alliance Management, Boehringer Ingelheim  Ruth McDermott, Commercial Development Manager, GE Healthcare  Bernard Vanhove, CEO, Effimune  Alan Urban, PhD, Echobrain  Clarence Deffaud, CEO/CSO, Biotem Finalists of the Innovation Prize 2014 - Michel Detheux representing iTeos Therapeutics iTeos is a private, biology-driven and preclinical-stage company, that leverages Catholic University of Louvain & Ludwig Cancer Research’s tumor immunology unique expertise to focus on discovery and development of small molecules designed to modify the tumor microenvironment. - Max Ostermeier representing Implandata Ophtalmic Products GmbH Implandata Ophtalmic Products GmbH is an ophthalmic device company, offering the most advanced solution for improved glaucoma care. With an implantable intraocular pressure sensor, it is possible for the first time to measure circadian IOP variations and IOP between office visits. By telemedical integration, it is possible to remotely manage glaucoma patients at lower cost and resulting in a better disease outcome. - Vincent Delattre representing G-Therapeutics: Ten years of academic research led to the development of fundamentally new treatment paradigms that restored voluntary locomotion in completely paralyzed animals with a success rate of 100%. G-therapeutics is translating these breakthroughs into a therapy for humans, and is developing an implantable spinal stimulation system and robotically assisted training program to rehabilitate spinal-cord-injured individuals. - Christoph Wiessner representing Asceneuron: Asceneuron develops a highly innovative drug for neurodegenerative diseases caused by the protein Tau. Our drug prevents Tau toxicity by targeting the enzyme O-GlcNAcase. It is planned to be first developed for Progressive supranuclear palsy (PSP), a fatal neurodegenerative disease that has no known treatment. It can then be applied to other Tauopathies, including Alzheimer's disease. - Frédéric Sottilini representing CarThera: The prognosis of patients with brain tumors is dramatically low. CarThéra aims to improve the prognosis of these patients using clinical stage medical devices. These devices are based on therapeutic ultrasound technology and allow for the diagnosis, treatment, and removal of tumors in a minimally invasive outpatient procedure (SonoProbe®) as well as for an improvement in the bioavailability of chemotherapeutics (SonoCloud®) by transiently opening the blood-brain barrier. The award Ceremony will take place on the Monday, October, 6th Biotech attendees: BIOTEM, Bioalternatives, Implandata Ophtalmic SA, Apceth GmbH, Asceneuron, TexiSense, Colcom, Vironexx, Lipopharma Therapeutics, Amplicel, ProteoDesign, NewVac, ReGenesys, EPhy-Science, BioLineRx, Phenocell, DNA Nexus, Centrose, Inventiva, Effimune, Screencell, Integragen, iTeos Therapeutics, HepaWash, Lunaphore, Genomic Vision, Acticor Biotech, Carmell Therapeutics, Viteava Pharmaceuticals Inc, Gliomune Therapeutics, Ibis Vision, PicoSeq, Rhenovia Pharma, Lasens, Bionicure, Bact’Up, Transcure, ZeClinics, CarThéra, G-Therapeutics, Aenitis Technologies, Hyprevention, Neuron Guard, Expert Ymaging... Pharma companies attendees: Laboratoires Servier, BASF, Sanofi, GlaxoSmithKline, Galderma, Roche, GE Healthcare, AbbVie, Ipsen, Novartis Pharma, EUSA Pharma, UCB Pharma, Janssen, Pierre Fabre, Orange Healthcare, AstraZeneca... And many other companies/organisations: Flanders Investment & Trade, SanaClis, University Autonoma of Barcelona, SATT, Liverpool School of Tropical Medicine, CNCPI, INSERM, Kurma Partners, Omnes Capital, Innova Software, De Gaulle Fleurance & Associés, CEA, Etablissement Francais du Sang, LaBiotech, Aquitaine Science Transfert, Vienna University of Technology, KLS Partners, FIST S.A., CNRS... SPONSORING We thank Cabinet de Gaulle Fleurance & Associés, GSK, Ipsen, Mayoly Spindler, Myriad Genetics, Pierre Fabre, Sanofi Pasteur, SATTs Association & Servier for their support. Innovation Days' Team 2014 Isabelle Levasseur + 33 (0)1 41 12 27 85 - Aurélia Ringard + 33 (0)1 41 12 27 71